Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination product containing budesonide, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties, and Gubenkechuan (also known as Gubenkechuan Keli), a traditional Chinese medicine formulation. Budesonide acts primarily by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammation in the airways or gastrointestinal tract[3][5]. Gubenkechuan Keli is used in China for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and may contain multiple herbal ingredients aimed at supporting lung function and reducing symptoms like cough, wheezing, and shortness of breath[6][10]. The combination aims to leverage both Western pharmacological anti-inflammatory effects (from budesonide) and traditional Chinese medicine approaches (from Gubenkechuan) for synergistic management of chronic respiratory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + gubenkechuan.